ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $3.85M rose 42.8% year over year, ahead of the +6.7% change in trailing-twelve-month other income / expenses. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +72.3% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +42.8% holds above the trailing-twelve-month pace of +6.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 13.54M USD
- Year-over-year change
- -10.0%
- 4-year CAGR
- +205.2%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.54M | -10.0% |
| FY2024 | 2024-12-31 | 15.05M | +49.2% |
| FY2023 | 2023-12-31 | 10.08M | +281.2% |
| FY2022 | 2022-12-31 | 2.65M | +1595.5% |
| FY2021 | 2021-12-31 | 156K | — |
Other Income / Expenses vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 other income / expenses of $14.69M is the 3rd highest of the 11 companies compared; the peer median is $2.43M.
- Its year-over-year change of +6.7% is the 5th highest of 11, against a peer median of -20.7%.
- Over three fiscal years its annual growth of +72.3% compares with a peer median of +96.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $42.51M | +18.6% | +121.9% | 196.7% | |
| LTM Sep 2026 | $21.88M | +45.3% | +141.8% | — | |
| LTM Mar 2026 | $14.69M | +6.7% | +72.3% | — | |
| LTM Mar 2026 | $11.81M | -31.7% | +52.7% | — | |
| LTM Mar 2026 | $11.63M | -10.2% | — | — | |
| LTM Mar 2026 | $3.76M | +136.9% | — | — | |
| LTM Mar 2026 | $1.11M | +28.9% | +96.6% | — | |
| LTM Mar 2026 | -$7.37M | -116.5% | — | 4.7% | |
| LTM Jun 2026 | -$12.2M | -156.1% | -18.4% | 7.2% | |
| LTM Mar 2026 | -$19.72M | -255.1% | — | 9.1% | |
| LTM Mar 2026 | -$23.11M | -31.1% | — | 46.6% | |
| Peer median (excluding ORIC) | $2.43M | -20.7% | +96.6% | 9.1% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.